EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Virus-free CRISPR knockin of a chimeric antigen receptor into KLRC1 generates potent GD2-specific natural killer cells

Keerthana Shankar, Isabelle Zingler-Hoslet, Diana M Tabima, Seth Zima, Lei Shi, Kirstan Gimse, Matthew H Forsberg, Varun Katta, Sage Z Davis, Daniel Maldonado, Brittany E Russell, Muhammed Murtaza und 4 weitere

Molecular Therapy · 2025-03 · 33 (3) · 1014-1030

DOI: 10.1016/j.ymthe.2025.01.024 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Therapy, 2025-03. Verfasst von Keerthana Shankar und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, University of Wisconsin-Madison, Madison, WI 53715, USA; Wisconsin Institute for Discovery, University of Wisco…. Hauptthemen laut MEDLINE: Killer Cells, Natural, Receptors, Chimeric Antigen, CRISPR-Cas Systems. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NIAID NIH HHS, NCRR NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Natural killer (NK) cells are an appealing off-the-shelf, allogeneic cellular therapy due to their cytotoxic profile. However, their activity against solid tumors remains suboptimal in part due to the upregulation of NK-inhibitory ligands, such as HLA-E, within the tumor microenvironment. Here, we utilize CRISPR-Cas9 to disrupt the KLRC1 gene (encoding the HLA-E-binding NKG2A receptor) and perform non-viral insertion of a GD2-targeting chimeric antigen receptor (CAR) within NK cells isolated from human peripheral blood. Genome editing with CRISPR-Cas9 ribonucleoprotein complexes yields efficient genomic disruption of the KLRC1 gene with 98% knockout efficiency and specific knockin of the GD2 CAR transgene as high as 23%, with minimal off-target activity as shown by CHANGE-seq, in-out PCR, amplicon sequencing, and long-read whole-genome sequencing. KLRC1 -GD2 CAR NK cells display high viability and proliferation, as well as precise cellular targeting and potency against GD2 + human tumor cells. Notably, KLRC1 -GD2 CAR NK cells overcome HLA-E-based inhibition in vitro against HLA-E-expressing, GD2 + melanoma cells. Using a single-step, virus-free genome editing workflow, this study demonstrates the feasibility of precisely disrupting inhibitory signaling within NK cells via CRISPR-Cas9 while expressing a CAR to generate potent allogeneic cell therapies against HLA-E + solid tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Killer Cells, NaturalReceptors, Chimeric AntigenCRISPR-Cas SystemsHumansGene EditingGene Knock-In TechniquesCell Line, TumorImmunotherapy, AdoptiveGangliosides

Stichwörter der Autor:innen

CARCRISPR-Cas9GD2KLRC1NK cellsNKG2Anon-viral

Substanzen

Receptors, Chimeric Antigenganglioside, GD2Gangliosides

Autor:innen und Institutionen

  • Department of Biomedical Engineering, University of Wisconsin-Madison, Madison, WI 53715, USA; Wisconsin Institute for Discovery, University of Wisconsin-Madison, Madison, WI 53715, USA.
  • Department of Biomedical Engineering, University of Wisconsin-Madison, Madison, WI 53715, USA.
  • Wisconsin Institute for Discovery, University of Wisconsin-Madison, Madison, WI 53715, USA.
  • Department of Biomedical Engineering, University of Wisconsin-Madison, Madison, WI 53715, USA; Department of Dermatology, University of Wisconsin-Madison, Madison, WI 53715, USA; Carbone Cancer Center, University of Wis…
  • Department of Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, WI 53715, USA; Carbone Cancer Center, University of Wisconsin-Madison, Madison, WI 53715, USA.
  • Department of Hematology, St Jude Children's Research Hospital, Memphis, TN 38105, USA.

Förderung

  • NCI NIH HHS
  • NIAID NIH HHS
  • NCRR NIH HHS
  • NIGMS NIH HHS
  • National Science Foundation Engineering Research Centers
  • Midwest Athletes Against Childhood Cancer
  • National Cancer Institute Division of Cancer Prevention
  • National Institutes of Health National Institute of Allergy and Infectious Diseases

Zitieren

APA

Shankar, K., Zingler-Hoslet, I., Tabima, D. M., Zima, S., Shi, L., Gimse, K., Forsberg, M. H., Katta, V., Davis, S. Z., Maldonado, D., Russell, B. E., Murtaza, M., Tsai, S. Q., Ayuso, J. M., Capitini, C. M., & Saha, K. (2025). Virus-free CRISPR knockin of a chimeric antigen receptor into KLRC1 generates potent GD2-specific natural killer cells. Molecular Therapy, 33(3), 1014-1030. https://doi.org/10.1016/j.ymthe.2025.01.024

Vancouver

Shankar K, Zingler-Hoslet I, Tabima DM, Zima S, Shi L, Gimse K, et al. Virus-free CRISPR knockin of a chimeric antigen receptor into KLRC1 generates potent GD2-specific natural killer cells. Molecular Therapy. 2025;33(3):1014-1030. doi:10.1016/j.ymthe.2025.01.024

BibTeX
@article{Shankar2025,
  author = {Shankar, Keerthana and Zingler-Hoslet, Isabelle and Tabima, Diana M and Zima, Seth and Shi, Lei and Gimse, Kirstan and Forsberg, Matthew H and Katta, Varun and Davis, Sage Z and Maldonado, Daniel and Russell, Brittany E and Murtaza, Muhammed and Tsai, Shengdar Q and Ayuso, Jose M and Capitini, Christian M and Saha, Krishanu},
  title = {Virus-free CRISPR knockin of a chimeric antigen receptor into KLRC1 generates potent GD2-specific natural killer cells},
  journal = {Molecular Therapy},
  year = {2025},
  volume = {33},
  number = {3},
  pages = {1014--1030},
  doi = {10.1016/j.ymthe.2025.01.024}
}
Kostenlos starten →